Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose sirolimus plus low-dose extended-release tacrolimus versus standard-dose extended-release tacrolimus after liver transplantation
NL-OMON44991Phase 3Active, not recruiting
- Sponsor
- Stichting Leveronderzoek
- Start
- Feb 2011
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sirolimus, tacrolimus and prednisone in liver transplant (2 arms), sponsored by Stichting Leveronderzoek. Primary endpoint: Percentage of patients with cGFR less than 60 mL/min at 36 months after transplantation. Started Feb 2011; status: active, not recruiting.
02
Drugs
sirolimustacrolimusprednisone
03
Conditions
liver transplant
Beyond the preview
Go deeper on NL-OMON44991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44991.